Tom Nevins

<i>In vitro</i> and <i>in vivo</i> activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

Wanda DePinto, Xin‐Jie Chu, Xuefeng Yin et al. · Molecular Cancer Therapeutics · 2006 · 103 citations · Full text

Medicine, Oncology, Pharmacology +14

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097

Wei He, Leopoldo Luistro, Daisy Carvajal et al. · Molecular Oncology · 2011 · 55 citations · Full text

Medicine, Immunology, Oncology +14

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

Xuefeng Yin, Leopoldo Luistro, Hua Zhong et al. · Clinical Cancer Research · 2013 · 48 citations · Full text

Medicine, Immunology, Pharmacology +17

Identification of novel, potent and selective inhibitors of Polo-like kinase 1

Shaoqing Chen, David Bartkovitz, Jianping Cai et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 33 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

Mark D. Pescovitz, Stuart J. Knechtle, Steven R. Alexander et al. · Pediatric Transplantation · 2007 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16